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Abstract: Mitochondrial dysfunction and systemic inflammation are major factors in the development
of sarcopenia, but the molecular determinants linking the two mechanisms are only partially
understood. The study of extracellular vesicle (EV) trafficking may provide insights into this
relationship. Circulating small EVs (sEVs) from serum of 11 older adults with physical frailty
and sarcopenia (PF&S) and 10 controls were purified and characterized. Protein levels of three
tetraspanins (CD9, CD63, and CD81) and selected mitochondrial markers, including adenosine
triphosphate 5A (ATP5A), mitochondrial cytochrome C oxidase subunit I (MTCOI), nicotinamide
adenine dinucleotide reduced form (NADH):ubiquinone oxidoreductase subunit B8 (NDUFB8),
NADH:ubiquinone oxidoreductase subunit S3 (NDUFS3), succinate dehydrogenase complex iron
sulfur subunit B (SDHB), and ubiquinol-cytochrome C reductase core protein 2 (UQCRC2) were
quantified by Western immunoblotting. Participants with PF&S showed higher levels of circulating
sEVs relative to controls. Protein levels of CD9 and CD63 were lower in the sEV fraction of PF&S
older adults, while CD81 was unvaried between groups. In addition, circulating sEVs from PF&S
participants had lower amounts of ATP5A, NDUFS3, and SDHB. No signal was detected for MTCOI,
NDUFB8, or UQCRC2 in either participant group. Our findings indicate that, in spite of increased
sEV secretion, lower amounts of mitochondrial components are discarded through EV in older adults
with PF&S. In-depth analysis of EV trafficking might open new venues for biomarker discovery and
treatment development for PF&S.
Keywords: aging; biomarkers; mitophagy; mitochondrial dynamics; mitochondrial quality control;
mitochondrial-derived vesicles (MDVs); exosomes; mitochondrial-lysosomal axis
1. Introduction
Advancing age is associated with declining muscle mass, function, and strength, a condition
referred to as sarcopenia which increases the risk of incurring negative health-related outcomes
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(e.g., disability, loss of independence, institutionalization, death) [1]. Hence, sarcopenia and its
clinical correlates are major public health priorities. Physical activity, nutritional interventions, and
multi-component programs have proven to be valuable strategies for managing sarcopenia [2–4]. Yet, no
effective pharmacological treatments are currently available to prevent, delay, or treat sarcopenia, which
is mostly due to the incomplete knowledge of the underlying pathophysiology [2]. To further complicate
the matter, at the clinical level, sarcopenia shows remarkable overlap with frailty, a “multidimensional
syndrome characterized by a decrease in physiological reserve and reduced resistance to stressors”,
often envisioned as a pre-disability condition [5]. Hence, the two conditions have been merged into a
new entity, referred to as physical frailty and sarcopenia (PF&S) [6].
Mitochondrial dysfunction and sterile inflammation are invoked among the pathogenic factors of
PF&S [7,8]. Derangements at different levels of the mitochondrial quality control (MQC) machinery
have been reported in older adults with PF&S [7]. However, whether and how cell-based alterations
may spread at the systemic level and impact muscle homeostasis is presently unknown.
One of the mechanisms by which cells communicate with each other involves a conserved delivery
system based on the generation and release of extracellular vesicles (EVs) [9]. These vesicles transfer
information between cells through several categories of cargo-enriched biomolecules (i.e., proteins,
lipids, nucleic acids, and sugars), each of them selectively influencing different cellular domains [10].
This shuttle system also contributes to degradative pathways responsible for eliminating oxidized cell
components, including mitochondria, by establishing inter-organelle contact sites [11]. In particular, in
the setting of incomplete mitochondrial depolarization, cells may either delay autophagy to remove
mildly damaged organelles or shift from mitophagy to the extrusion of mitochondrial components
within EVs [12,13]. As such, the generation and release of mitochondrial-derived vesicles (MDVs) may
represent a complement to MQC systems before whole-sale organelle is triggered [13,14].
Cell-free mitochondrial DNA (mtDNA) has been identified among the molecules released
within exosomes that may act as damage-associated molecular patterns (DAMPs) [15]. One of the
biological roles for these molecules is the activation of innate immunity through binding of their
hypomethylated CpG motifs, resembling those of bacterial DNA, to membrane- or cytoplasmic-pattern
recognition receptors (PRRs), including Toll-like receptor (TLR), nucleotide-binding oligomerization
domain (NOD)-like receptor (NLR) [16], and cytosolic cyclic GMP-AMP synthase (cGAS)-stimulator of
interferon genes (STING) DNA sensing system-mediated pathways [17]. However, mtDNA is not the
only mitochondrial constituent that may be displaced via MDVs and trigger these responses. Recently,
the extrusion of mitochondrial components other than mtDNA has been reported within small EVs
(sEVs) purified from the serum of older adults with Parkinson’s disease (PD) [14]. However, whether
and how this mechanism is in place in the setting of PF&S is unexplored.
In the present study, we purified sEVs from older adults with and without PF&S, quantified
their amount, and characterized their content for the presence of mitochondrial components. The
identification of specific derangements in sEVs in PF&S may shed light on its pathophysiology as well
as suggest new biomarkers and possible biological targets for drug development.
2. Materials and Methods
2.1. Participants
Older adults aged 70+ with and without PF&S were recruited among the participants of the
“BIOmarkers associated with Sarcopenia and Physical frailty in EldeRly pErsons” (BIOSPHERE)
study [18]. BIOSPHERE was designed to determine and validate a panel of PF&S biomarkers through
multivariate statistical modeling of biomolecules pertaining to inflammation, redox homeostasis, amino
acid metabolism, neuromuscular junction dysfunction, and muscle remodeling pathways [18–20].
The operational definition used in the “Sarcopenia and Physical fRailty IN older people:
multi-componenT Treatment strategies” (SPRINTT) project [21,22] was applied to diagnose PF&S: (a)
physical frailty, based on a summary score on the Short Physical Performance Battery (SPPB) [23]
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between 3 and 9, (b) low appendicular muscle mass (aLM), according to the cut-points proposed by
the Foundation for the National Institutes of Health (FNIH) sarcopenia project [24], and (c) absence
of mobility disability (i.e., inability to complete the 400-m walk test) [25]. The present investigation
involved a convenience sample of 21 participants, 11 older adults with PF&S and 10 non-sarcopenic
non-frail (non-PF&S) controls. Participants were randomly chosen from the cohort of the BIOSPHERE
study [18], among those from whom serum was available for vesicle purification.
The study was approved by the Ethics Committee of the Università Cattolica del Sacro Cuore
(Rome, Italy; protocol number BIOSPHERE: 8498/15) and all participants signed an informed consent
prior to inclusion. Study procedures and criteria for participant selection were described thoroughly
elsewhere [18].
2.2. Measurement of Appendicular Lean Mass by Dual X-Ray Absorptiometry
Appendicular lean mass was quantified through whole-body Dual X-Ray Absorptiometry (DXA)
scans on a Hologic Discovery A densitometer (Hologic, Inc., Bedford, MA, USA) according to the
manufacturer’s procedures. Criteria for low aLM were as follows: (a) aLM to body mass index (BMI)
ratio (aLMBMI) < 0.789 in men and <0.512 in women, or (b) crude aLM < 19.75 kg in men and <15.02 kg
in women [24].
2.3. Blood Sampling
Blood samples were collected in the morning by venipuncture of the median cubital vein after
overnight fasting, using commercial collection tubes (BD Vacutainer®; Becton, Dickinson and Co.,
Franklin Lakes, NJ, USA). One blood tube was delivered to the centralized diagnostic laboratory of
the Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS (Rome, Italy) for standard blood
biochemistry. The remaining tubes were processed for serum collection in the Biogerontology lab of
the Università Cattolica del Sacro Cuore (Rome, Italy). Serum separation was obtained after 30 min of
clotting at room temperature and subsequent centrifugation at 1000× g for 15 min at 4 ◦C. The upper
clear fraction (serum) was collected in 0.5-mL aliquots and stored at −80 ◦C until analysis.
2.4. Small Extracellular Vesicles Isolation and Characterization
2.4.1. Purification of Small Extracellular Vesicles by Differential Ultracentrifugation
Small EVs/exosomes were purified through differential centrifugation as previously described [14,26].
Briefly, serum samples were diluted with equal volumes of phosphate-buffered saline (PBS) to reduce
fluid viscosity. Diluted samples were centrifuged at 2000× g at 4 ◦C for 30 min and pellets were discarded
to remove cell contaminants. Subsequently, supernatants were centrifuged at 12,000× g at 4 ◦C for 45 min
to remove apoptotic bodies, mitochondrial fragments, cell debris, and large vesicles (mean size > 200 nm).
Supernatants were collected and ultracentrifuged at 110,000× g at 4 ◦C for 2 h. Pellets were recovered
and resuspended in PBS, filtered through a 0.22-µm filter, and ultracentrifuged at 110,000× g at 4 ◦C for
70 min to eliminate contaminant proteins. Pellets enriched in purified sEVs were finally resuspended in
100 µL of PBS. To quantify sEVs, total protein concentration was measured using the Bradford assay [27].
2.4.2. Western Immunoblot Analysis of Small Extracellular Vesicles
Western immunoblot analysis was performed to assess the purity of sEV isolation, to determine
the type of sEVs on the basis of the expressed tetraspanins, and to characterize their protein cargo as
previously described [14,28]. Briefly, equal amounts (1.25 µg) of sEV proteins were separated by sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and subsequently electroblotted
onto polyvinylidenefluoride (PVDF) Immobilon-P (Millipore, Burlington, MA, USA). Membranes
were probed with primary antibodies against tetraspanins CD63 (1:200), CD9 (1:200), CD81 (1:200), a
specific cocktail of antibodies (1:250) targeting mitochondrial markers (Table 1), flotilin (1:200), and
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heterogeneous nuclear ribonucleoprotein A1 (HNRNPA1; 1:1000). Technical specifications of primary
antibodies used for Western immunoblotting are detailed in Supplementary Table S1.
Table 1. Mitochondrial components and related electron transport chain complexes assayed in purified









Abbreviations: ATP5A, adenosine triphosphate 5A; ETC, electron transport chain; MTCOI, mitochondrial cytochrome
C oxidase subunit I; NDUFB8, nicotinamide adenine dinucleotide reduced form (NADH):ubiquinone oxidoreductase
subunit B8; NDUFS3, NADH:ubiquinone oxidoreductase subunit S3; SDHB, succinate dehydrogenase complex iron
sulfur subunit B; UQCRC2, ubiquinol-cytochrome C reductase core protein 2.
The following day, membranes were incubated for 1 h at room temperature with anti-mouse
peroxidase-conjugated secondary antibodies (1:2000) (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Blots were visualized using the Clarity Max ECL Western Blotting Substrate (Bio-Rad Laboratories)
and images were acquired by the ChemiDoc MP Imaging System and analyzed by Image Lab TM
software version 6.0.1 (Bio-Rad Laboratories). Values of optical density (OD) units of each protein
band immunodetected were normalized for the amount of sEV total proteins, as determined by the
Bradford assay, and related to the control group, whose OD was set at 100%.
2.4.3. Analysis of Small Extracellular Vesicles by Scanning Electron Microscopy Imaging
Small EVs were fixed in a solution of 3.7% glutaraldehyde (Sigma–Aldrich, St. Luis, MO, USA)
in PBS for 15 min, washed twice with PBS, and dehydrated through a series of ascending grades of
ethanol (i.e., 40%, 60%, 80%, 96%–98%). Subsequently, samples were mounted on carbon adhesive
stubs (Agar Scientifics, Stansted, UK) and left at room temperature for 24 h to obtain complete ethanol
evaporation. Samples were gold-coated with a Balzers SCD 040 sputter coater (BAL–TEC AG, Balzers,
Lichtenstein, Germany; thickness of gold layer: 40 nm) and analyzed at 132.21 K× magnification
by a ZEISS EVO HD 15 Scanning Electron Microscope (Carl Zeiss Microscopy GmbH, Oberkochen,
Germany) operating under high-vacuum at an accelerating voltage of 5 kV.
2.5. Statistical Analysis
Descriptive statistics were run on all data. Differences in demographic, anthropometric, and
clinical parameters between PF&S and control participants were assessed via t-test statistics and χ−2 or
Fisher exact tests, for continuous and categorical variables, respectively. All tests were two-sided, with
statistical significance set at p < 0.05. Analyses were performed using the GraphPrism 5.03 software
(GraphPad Software, Inc., San Diego, CA, USA).
3. Results
3.1. Characteristics of the Study Participants
The subset of participants included in the present study was representative of the whole
BIOSPHERE cohort in terms of age, sex distribution, clinical characteristics, and body composition and
functional parameters [8]. The main characteristics of study participants are presented in Table 2. Sex
distribution, BMI, number of comorbid conditions and medications, total serum protein concentrations,
and albumin levels did not differ between older adults with and without PF&S. PF&S participants
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tended to be older than controls, but the difference did not reach statistical significance. As per the
selection criteria, SPPB scores and aLM either crude or adjusted by BMI were lower in older adults
with PF&S relative to non-PF&S participants.
Table 2. Participant characteristics according to the presence of physical frailty and sarcopenia.
Characteristic Non-PF&S (n = 10) PF&S (n = 11) p-Value
Age (years), mean ± SD 73.9 ± 2.7 77.7 ± 5.4 0.0557
Gender (female), n (%) 5 (50) 8 (73) 0.5344
BMI (kg/m2), mean ± SD 28.1 ± 2.8 30.3 ± 4.3 0.1891
SPPB summary score, mean ± SD 12.0 ± 1.0 7.0 ± 0.3 <0.0001
aLM (kg), mean ± SD 20.21 ± 4.10 15.84 ± 3.63 0.0390
aLMBMI, mean ± SD 0.81 ± 0.32 0.51 ± 0.11 0.0118
Albumin (g/L), mean ± SD 45.4 ± 12.7 39.8 ± 1.2 0.1536
Total serum protein concentration (g/L), mean ± SD 71.8 ± 4.6 75.5 ± 3.1 0.0914
Number of diseases ¥, mean 3.2 ± 1.6 3.1 ± 1.2 0.8647
Number of medications #, mean ± SD 2.9 ± 1.6 3.2 ± 1.8 0.7061
Abbreviations: aLM, appendicular lean mass; aLMBMI, aLM adjusted by body mass index (BMI); non-PF&S,
non-physically frail non-sarcopenic; PF&S: physical frailty & sarcopenia; SD: standard deviation; SPPB: short
physical performance battery. ¥ includes hypertension, coronary artery disease, prior stroke, peripheral vascular
disease, diabetes, chronic obstructive pulmonary disease, and osteoarthritis. # includes prescription and
over-the-counter drugs
3.2. Characterization of Small Extracellular Vesicles from the Serum of Participants with and without Physical
Frailty and Sarcopenia
3.2.1. Verification of the Purity of Serum Small Extracellular Vesicles
The purity of sEVs obtained by serum ultracentrifugation was ascertained according to the
guidelines of the International Society of Extracellular Vesicles [29]. In particular, the presence of the
cytosolic protein flotilin (positive control) and the absence of the non-sEV component HNRNPA1
(negative control) were verified (Figure 1A). The purified biospecimen was also analyzed by scanning
electron microscopy (SEM) to confirm enrichment in sEVs. Small EVs appear in the scanning electron
micrographs as objects of spherical shape and less than 100 nm in size (Figure 1B).
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  Figure 1. (A) Blots of the cytosolic protein flotilin and heterogeneous nuclear ribonucleoprotein A1
(HNRNPA1) as positive and negative markers respectively, in purified small extracellular vesicles (sEVs)
obtained by serum ultracentrifugation from participants with physical frailty and sarcopenia (PF&S)
and non-physically frail non-sarcopenic (non-PF&S) controls. The Michigan Cancer Foundation-7
(MCF-7) cell extract was used as the positive control for the anti-HNRNPA1 antibody. (B) Scanning
electron micrographs of purified sEVs. The white-dashed box delimitates the area zoomed on the right.
White arrows indicate some of the sEVs found in the observation field. Scale bar: 100 nm.
3.2.2. Quantification of the Amount of Circulating Small Extracellular Vesicles
The total amount of sEVs purified from the serum of PF&S participants was significantly greater
than in non-PF&S controls (p < 0.0001, Figure 2).
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Figure 2. Serum levels of small extracellular vesicles (sEVs) in non-physically frail non-sarcopenic
(non-PF&S) controls (n = 10) and participants with physical frailty and sarcopenia (PF&S; n = 11).
Data were normalized for the amount of total serum proteins and are shown as percentage of the
control gr up set at 100%. Bars represent mean values (±standard error of the mean). * p < 0.05 versus
non-PF&S.
3.2.3. Characterization of the Origin and Cargo of Small Extracellular Vesicles
Protein levels of the two tetraspanins, CD9 and CD63, were lower in participants with PF&S than
in non-PF&S controls (Figure 3A,B), while CD81 content was unvaried between groups (Figure 3C).
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(sEVs) from n n-physically frail non-sarcopenic (non-PF&S) controls (n = 10) and participants with
physical frailty and sarco enia (PF&S; n = 11). Data were normalized for the amount of sEV total
proteins and are shown as percentage of the control group set at 100%. Bars represent mean values
(±standard error of the mean). * p < 0.0001 versus non-PF&S.
As for sEV cargo characterization, protein levels of adenosine triphosphate 5A (ATP5A; complex
V), nicotinamide adenine dinucleotide reduced form (NADH):ubiquinone oxidoreductase subunit S3
(NDUFS3; complex I), and succinate dehydrogenase complex iron sulfur subunit B (SDHB; complex
II) were lower in participants with PF&S than in non-PF&S controls (Figure 4A–C). No signal was
detected for mitochondrial cytochrome C oxidase subunit I (MTCOI, complex IV), NADH:ubiquinone
oxidoreductase subunit B8 (NDUFB8; complex I), or ubiquinol-cytochrome C reductase core protein 2
(UQCRC2; complex III) in either participant group.
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dehydrogenase complex iron sulfur subunit (SDHB) in purified small extracellular vesi l s (sEVs) from
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and sarcopenia (PF&S; n = 11). Data were normalized for the amount of sEV total protein and are
sh wn as percentage of the control group set at 100%. Bars r present mean values (±s andard error of
the mean). * p < 0.0001 versus non-PF&S.
4. Discussion
Among the factors involved in muscle degeneration associated with PF&S, mitochondrial
dysfunction and the accrual of abnormal organelles have been indicated as relevant players [30].
However, the exact mechanisms underlying mitochondrial decay are not completely deciphered.
Derangements in MQC processes have been reported in older adults with PF&S [7,31,32].
Nevertheless, alterations in sEV trafficking, which might contribute to MQC dyshomeostasis in
muscle [33], have remained largely unexplored. To start filling this gap in knowledge, we purified sEVs
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from the serum of older adults with and without PF&S and, after ascertaining purity of the preparation,
we determined the overall quantity of the mixed sEV population. Our results show a greater amount
of sEVs in serum of PF&S participants compared with non-PF&S controls (Figure 2). The verification of
the three tetraspanins, CD9, CD63, and CD81, in purified sEVs allowed these vesicles to be identified
as a fraction of endosome-derived vesicles, referred to as exosomes, originating from the fusion of
multivesicular bodies with the plasma membrane [28]. A lower protein expression of CD9 and CD63
was found in the exosome fraction purified from participants with PF&S (Figure 3), while levels of
CD81 were comparable between groups. These observations are in keeping with the heterogenous
composition of exosomes themselves, likely reflecting a different vesicle trafficking regulation [34].
Indeed, RAB27A, a guanosine triphosphatase (GTPase) that modulates exosome secretion, has been
shown to regulate the secretion of CD63-positive exosomes, but not of those positive for CD9 [35].
Notably, exosomes derived by B-cells are characterized by the tetraspanin markers CD9 and CD81,
while CD63 is absent [36]. A previous report by our group showed that RAB7A, a small GTPase
and a master regulator of the late endocytic pathway, was able to modulate secretion of CD9- and
CD81-positive exosomes [37]. The decreased expression of tetraspanin CD63 found in the present
study may therefore be indicative of an altered late endocytic pathway [38], possibly suggesting
disarrangements in late endocytic trafficking in PF&S.
The identification of mitochondrial components within the purified material allowed for
classification of MDVs among sEVs. In particular, lower levels of the mitochondrial components
ATP5A (complex V), NDUFS3 (complex I), and SDHB (complex II) were found in participants
with PF&S (Figure 4). With the intent of preserving mitochondrial homeostasis, mitochondrial
hyper-fission segregates severely damaged or unnecessary organelles [39,40] that are subsequently
disposed via mitophagy [41]. However, mitochondrial-lysosomal crosstalk may dispose mildly
oxidized mitochondria via MDV release [42]. Such a mechanism may therefore restore mitochondrial
homeostasis before whole-sale organelle degradation is triggered [42]. Though, in the case of defective
mitophagy or disruption of the mitochondrial-lysosomal axis, accrual of damaged mitochondria,
misfolded proteins, and lipofuscin may occur as a result of inefficient cellular quality control [43].
Therefore, the increased sEV secretion in participants with PF&S (Figure 2) might reflect the cell’s
attempt to extrude dysfunctional mitochondria. However, the reduced secretion of MDVs in the
same participant group (Figure 4) may indicate that the MQC flux is impaired or that the damage to
mitochondria is too severe to be disposed via MDVs. This idea is in keeping with previous reports
by our group showing derangements in the expression of key proteins of the MQC machinery in old
hip-fractured patients with sarcopenia [7,31].
The retrieval of mitochondrial components within sEVs is particularly relevant as it provides
novel insights into the mechanisms of sterile inflammation, an age-associated inflammatory response
mounted in the absence of infections [44]. This process is framed within the innate immune response
and has been included as part of the “danger theory” of inflammation [45]. According to this view,
misplaced noxious material from injured cells (i.e., damage-associated molecular patterns (DAMPs))
triggers caspase-1 activation and the secretion of pro-inflammatory cytokines [46]. The release of MDV
content (e.g., mitochondrial proteins, mtDNA) can activate inflammatory pathways by interacting with
several receptors/systems including TLRs, family pyrin domain-containing 3 (NLRP3) inflammasome,
and cGAS-STING DNA sensing system [47].
Recently, we described the existence of a frailty “cytokinome” in older adults with PF&S defined
by higher levels of P-selectin, C-reactive protein, and interferon-γ-induced protein 10, and lower levels
of myeloperoxidase, interleukin 8, monocyte chemoattractant protein-1, macrophage inflammatory
protein 1-α, and platelet-derived growth factor BB [8]. Pro-sarcopenic/pro-disability effects have
traditionally been attributed to inflammation [48,49] as much as to dysfunction of anti-inflammatory
pathways [49,50]. Furthermore, circulating MDVs have been identified in serum of older adults with
PD and associated with a specific inflammatory profile [14]. However, the liaison among failing
mitochondrial fidelity pathways, MDV secretion, and systemic inflammation may not be exclusive
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of neurodegeneration. Indeed, other conditions, such as HIV infection, a model of accelerated and
accentuated aging [51], are characterized by pyroptotic bystander cell death and release of DAMPs that
may trigger the same pathways as those identified in PD and inflamm-aging [52]. In addition, a massive
release of DAMPs is acknowledged as a factor in the development of multiorgan failure in patients
with severe injuries or during hemorrhagic shock [53]. Although the pathophysiology of multiple
organ failure syndrome, neurodegeneration, and PF&S is heterogeneous, the release of mitochondrial
DAMPs might be a converging mechanism shared by all of them. Should this assumption hold true,
the scavenging of circulating mitochondrial DAMPs might represent a yet unexplored therapeutic
option for the management of age-associated disarrangements, including PF&S. From this perspective,
our findings are in line with the geroscience hypothesis, according to which the roots of most chronic
diseases may reside in perturbations of a set of basic mechanisms (i.e., hallmarks of aging), including
mitochondrial dysfunction [54].
Albeit presenting novel and promising findings, our work has limitations that need to be discussed.
First of all, the cross-sectional design of the study precludes establishing cause–effect or temporal
relationships between the analyzed pathways and PF&S pathophysiology. Also, although participants
were carefully selected and thoroughly characterized, we cannot rule out the possibility that unknown
comorbidities may have affected our results. In addition, our study provides an initial characterization
of the heterogeneous population of circulating sEVs. Indeed, the analysis of the MDV cargo was limited
to selected components/subunits of the mitochondrial electron transport chain. Hence, we cannot
exclude that the analysis of other biomolecules, including mtDNA, that may be transported along the
same road could provide additional insights into the relationship between sEV trafficking and PF&S.
Finally, a deeper characterization of sEVs for their structure and content by means of transmission
electron microscopy analysis is needed to confirm and expand our findings as well as to gain further
information into the dynamic regulation of vesicle trafficking in PF&S.
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